Updates in CML: recent trials and novel agents
Description: Highlights of promising clinical trials of novel agents for chronic myeloid leukemia (CML) are overviewed here by Susanne Saussele, MD, of the University of Mannheim, Mannheim, Germany. Discussed are Phase I trial of the BCR-ABL inhibitor ABL001 (NCT02081378), and the use of ponatinib as a second line therapy. Prof. Saussele herself is working on the EURO-SKI trial (NCT01596114) in individuals with late relapse CML, partially assessing the effects of halting treatment with imatinib, nilotinib and dasatinib, and she holds promise for the upcoming results. This interview took place at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.
Shared By : VJHemOnc
Posted on : 08/06/18
Added : 7 months ago